Opaleye Management Inc. Trevi Therapeutics, Inc. Transaction History
Opaleye Management Inc.
- $508 Million
- Q4 2024
A detailed history of Opaleye Management Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Opaleye Management Inc. holds 2,317,500 shares of TRVI stock, worth $10.5 Million. This represents 1.94% of its overall portfolio holdings.
Number of Shares
2,317,500
Previous 2,567,990
9.75%
Holding current value
$10.5 Million
Previous $8.58 Million
15.1%
% of portfolio
1.94%
Previous 1.57%
Shares
8 transactions
Others Institutions Holding TRVI
# of Institutions
114Shares Held
77.6MCall Options Held
218KPut Options Held
182K-
Nea Management Company, LLC Timonium, MD11.4MShares$51.4 Million3.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.7MShares$48.2 Million2.72% of portfolio
-
Viking Global Investors LP4.4MShares$19.9 Million0.06% of portfolio
-
Rubric Capital Management LP New York, NY4.21MShares$19 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.15MShares$18.8 Million0.04% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $264M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...